Skip to main content
BioCardia, Inc. logo

BioCardia, Inc. — Investor Relations & Filings

Ticker · BCDA ISIN · US09060U5074 LEI · 5493003EDBXRQRW22O75 US Manufacturing
Open in API
Filings indexed 1,022 across all filing types
Latest filing 2023-09-01 Proxy Solicitation & In…
Country US United States of America
Listing US BCDA

About BioCardia, Inc.

https://www.biocardia.com/

BioCardia, Inc. is a clinical-stage regenerative medicine company that develops cellular and cell-derived therapeutics for cardiovascular and pulmonary diseases. The company's lead program is the CardiAMP® cell therapy system, an autologous therapy that uses a patient's own bone marrow cells to potentially stimulate the body's natural healing response in the heart. This therapy is primarily being evaluated for the treatment of ischemic heart failure. In addition to its autologous platform, BioCardia is also developing CardiALLO™, an allogeneic cell therapy platform using cells from qualified donors. The company's approach integrates biotherapeutic candidates with proprietary delivery systems for targeted administration.

Recent filings

Filing Released Lang Actions
FORM DEF 14A
Proxy Solicitation & Information Statement
2023-09-01 English
FORM 8-K
Board/Management Information Classification · 95% confidence The document is a Form 8-K Current Report filed with the SEC by BioCardia, Inc. dated August 21, 2023. It announces the date and details of the upcoming Annual Meeting of Stockholders, including the record date for voting and deadlines for shareholder proposals and director nominations. The content focuses on shareholder director nominations and procedural information related to the Annual Meeting, not the meeting materials themselves or voting results. This type of announcement about board and shareholder meeting matters fits best under Board/Management Information (MANG), as it relates to board nominations and governance event announcements. The document is not a proxy statement, voting results, or a full report, but an 8-K filing announcing board-related shareholder nomination information. Confidence is high due to clear SEC form type and content focus on board and shareholder nomination information.
2023-08-21 English
FORM 4/A
Director's Dealing
2023-08-18 English
FORM 4/A
Director's Dealing
2023-08-18 English
FORM 4
Director's Dealing
2023-08-17 English
FORM 4
Director's Dealing
2023-08-14 English

Browse filings by year

24 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.